Market Access Orphan drugs - Germany and the EU5
19.01.2021 13:59
This online seminar provides you with market access know-how at the EU level and valuable insights into the five most interesting markets: Germany, the UK, Spain, Italy and France.
Aims and objectives:
This online seminar helps you plan the market access of your orphan drug in the EU, specifically in the EU5: the UK, France, Italy, Germany and Spain. Industry and authority experts discuss regulatory challenges in marketing authorisation and HTA, and provide practical hints on how to plan a launch.
-How do you successfully cooperate with stakeholders?
-How do you plan your marketing campaign?
-How do you successfully cooperate with stakeholders?
-How do you plan your marketing campaign?
Topics:
- Marketing authorisation: Relevance of registration data and conditions
- Market access in the EU: National and supranational approaches
- HTA and market access in the UK, France, Italy and Spain
- Marketing authorisation: Relevance of registration data and conditions
- Market access in the EU: National and supranational approaches
- HTA and market access in the UK, France, Italy and Spain
- Orphan drugs in the German AMNOG process
- Preparing for a launch in Germany
- Preparing for a launch in Germany
Who should attend?
This online seminar is of value to anyone contributing to the successful market entry of their orphan drugs in the EU, especially in Germany, France, the UK, Spain and Italy.
